

2021 Educational Symposium Programme



Low-dose aspirin for the prevention of atherothrombosis across the cardiovascular risk continuum

Friday 28th May 2021 - 1pm-5pm
Shanghai



Introduction

The International Aspirin Foundation (IAF), founded in 1974, aims to increase knowledge, understanding and medical interest in aspirin, by sharing information and stimulating research interest and discussion about all aspects of aspirin.

IAF is particularly honoured to have been invited to present its first ever symposium in China, at the 2021 Oriental Congress of Cardiology (OCC). The President of OCC, Professor Junbo GE, will be joined by the Chair of the IAF Scientific Advisory Board, Professor Carlo Patrono, to chair the sessions. This will be a hybrid event.


In addition, IAF is also deeply honoured to have Professor Xue-Bo Liu welcome delegates to the event.

Background and Rationale:

Cardiovascular risk represents a continuous variable, ranging from the low level of apparently healthy, middle-age, asymptomatic subjects to the high level of patients in the acute phase of a major vascular event, with intermediate levels of risk defined by the presence of metabolic (e.g. diabetes mellitus) or myeloproliferative (e.g. polycythemia vera) disorders, or definitive evidence (e.g. by imaging) of coronary or peripheral arterial disease.

Low-dose aspirin is unique among the currently available antithrombotic drugs in having been assessed for efficacy and safety across the whole spectrum of the cardiovascular risk continuum, in placebo-controlled trials ranging in size from a few hundred to forty-thousand subjects, and in duration from a few weeks to 10 years. The overall positive results of these trials have provided level A evidence for treatment recommendations addressing subjects across the cardiovascular risk continuum, such as those provided by the 2019 guidelines of the European Society of Cardiology (Diabetes Guideline and Chronic Coronary Syndromes Guideline) and American Heart Association/American College of Cardiology (Primary Prevention Guideline).

The aim of the International Aspirin Foundation Symposium is to provide a forum for the presentation and discussion of the established facts and open questions concerning the use of low-dose aspirin for the primary and secondary prevention of atherothrombosis, as reviewed by leading experts from China, Europe and USA, with a view at identifying similarities and discrepancies among the different approaches to prevention.



2021 Educational Symposium Programme



Welcome
Prof. Xue-Bo Liu



Chairpersons
Prof. Junbo Ge
and Prof. Carlo Patrono



1.00pm - 1.05pm	Introduction Prof. Junbo Ge, Fudan University, Shanghai Prof. Carlo Patrono, Catholic University, Rome	 
1.05pm - 1.25pm	Mechanistic insight into how aspirin prevents atherothrombosis Prof. Carlo Patrono, Catholic University, Rome	
1.25pm - 1.55pm	Prevention of serious vascular events by low-dose aspirin across the cardiovascular risk continuum Prof. Mike Gaziano, Harvard University, Boston	
1.55pm - 2.25pm	Prevention of serious vascular events by low-dose aspirin across the cardiovascular continuum in China Prof. Xiaoying Li, Chinese PLA General Hospital, Beijing	
2.25pm - 2.50pm	Discussion	
2.50pm - 3.20pm	Low-dose aspirin for the secondary prevention of stroke Prof. Peter Rothwell, University of Oxford, Oxford	
3.20pm - 3.30pm	Discussion	
3.30pm - 4.00pm	Dual-pathway inhibition for secondary antithrombotic prevention in cardiovascular disease Prof. Wei-Guo Fu, Fudan University, Shanghai	
4.00pm - 4.10pm	Discussion	
4.10pm - 4.40pm	How to improve the gastrointestinal safety of low-dose aspirin Prof. Andrew T Chan, Harvard University, Boston	
4.40pm - 4.50pm	Discussion	
4.50pm - 5.00pm	Summary/closing remarks Prof. Junbo Ge, Fudan University, Shanghai Prof. Carlo Patrono, Catholic University, Rome	 

Conference Registration is available at www.occmd.org